Second Sight Medical Products Inc (NASDAQ:EYES) fell 0% on Tuesday . The stock traded as low as $1.45 and last traded at $1.51. 2,580,000 shares traded hands during trading, an increase of 237% from the average session volume of 766,395 shares. The stock had previously closed at $1.51.
Several brokerages recently weighed in on EYES. HC Wainwright set a $5.00 price target on shares of Second Sight Medical Products and gave the company a “buy” rating in a research report on Monday, February 5th. Zacks Investment Research raised shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Monday, January 8th.
The stock has a market cap of $85.78, a PE ratio of -2.33 and a beta of 3.46.
About Second Sight Medical Products
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.